Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…
Summit Therapeutics Inc.
Next earnings ≈ Jul 30, 2026 · est. from filing cadence
Last earnings +3.0% on 2026-04-30
Conservative balance sheet (liabilities/equity 0.14x).
Rules-based read computed from SEC figures — no Anthropic key set. Add ANTHROPIC_API_KEY to .env.local for a full Claude analysis.
Summit Therapeutics Inc. shows $0.00 in FY2024 revenue, and -163.9% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
Sources: SEC EDGAR (CIK 0001599298, latest 10-Q filed 2026-04-30) · EODHD · rules-based read · as of 6/18/2026, 12:12:33 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $1.81M | $705K | $0.00 | $0.00 | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$86.2M | -$72.1M | -$610M | -$226M | — |
| Net income | -$88.6M | -$78.8M | -$615M | -$221M | -$1.08B |
| Diluted EPS | -$0.67 | -$0.41 | -$0.99 | -$0.31 | -$1.44 |
| Net margin | -4897.8% | -11174.8% | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
501 tracked peers · median
Last 90 days: 6 open-market buys · 0 sales
| 2026-06-12 | Zanganeh Mahkam Co-Chief Executive Officer | Buy | 3.81M @ $13.12 | $50.0M |
| 2026-06-12 | DUGGAN ROBERT W Co-Chief Executive Officer | Buy | 3.81M @ $13.12 | $50.0M |
| 2026-06-04 | DUGGAN ROBERT W Co-Chief Executive Officer | Buy | 100K @ $14.60 | $1.46M |
| 2026-06-04 | Zanganeh Mahkam Co-Chief Executive Officer | Buy | 100K @ $14.60 | $1.46M |
| 2026-06-04 | Soni Manmeet Singh COO and CFO | Buy | 25.0K @ $14.46 | $362K |
| 2026-06-04 | Soni Manmeet Singh COO and CFO | Buy | 25.0K @ $14.43 | $361K |